Get the Stockscreener App
3.10
54.23%
1.09
After Hours:
3.11
0.010
+0.32%
Tvardi Therapeutics Inc stock is traded at $3.10, with a volume of 70.39M.
It is up +54.23% in the last 24 hours and up +7.27% over the past month.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
See More
Previous Close:
$2.01
Open:
$2.13
24h Volume:
70.39M
Relative Volume:
57.84
Market Cap:
$29.08M
Revenue:
$2.14M
Net Income/Loss:
$-15.44M
P/E Ratio:
-1.0017
EPS:
-3.0946
Net Cash Flow:
$-24.67M
1W Performance:
+63.16%
1M Performance:
+7.27%
6M Performance:
-20.31%
1Y Performance:
-85.59%
1-Day Range:
$2.06
$3.8599
1-Week Range:
$1.8043
$3.8599
52-Week Range:
$1.50
$43.65
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
Name
Tvardi Therapeutics Inc
Sector
Industry
Phone
(713) 489-8654
Address
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
Compare TVRD vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
3.10 | 18.86M | 2.14M | -15.44M | -24.67M | -3.0946 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-14-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-14-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Oct-13-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-13-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-14-25 | Initiated | Raymond James | Outperform |
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-25 | Initiated | Piper Sandler | Overweight |
| May-21-25 | Initiated | Oppenheimer | Outperform |
| May-15-25 | Initiated | BTIG Research | Buy |
| Jun-13-24 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jun-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-13-24 | Downgrade | Needham | Buy → Hold |
| Jun-13-24 | Downgrade | Stifel | Buy → Hold |
| Mar-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-08-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-01-21 | Resumed | Canaccord Genuity | Buy |
| Aug-03-21 | Initiated | JP Morgan | Neutral |
| Apr-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-12-19 | Reiterated | H.C. Wainwright | Buy |
| May-29-19 | Reiterated | Laidlaw | Buy |
| Feb-06-19 | Resumed | Jefferies | Buy |
| Jan-15-19 | Initiated | BofA/Merrill | Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Jefferies | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jun-28-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-12-18 | Resumed | H.C. Wainwright | Buy |
| Feb-12-18 | Upgrade | Janney | Neutral → Buy |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
View All
Tvardi Therapeutics Inc Stock (TVRD) Latest News
Tvardi Therapeutics (TVRD) Study result Summary - Quartr
Why Tvardi Therapeutics (TVRD) Stock Is Up Today - Quiver Quantitative
TVRD Reiterated by BTIG -- Price Target Maintained at $15.00 - GuruFocus
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) stock jumps as Phase 1 data puts cash-value biotech under heavy churn - TechStock²
Why Is Tvardi Therapeutics Stock Gaining Tuesday? - Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Tvardi Therapeutics (Nasdaq: TVRD) Soars on Positive Phase 1 Results for Next-Gen STAT3 Inhibitor TTI-109 - Investorideas.com
With tardy Tvardi phase I win, skin in STAT3 game plus GI - BioWorld News
Tvardi reports 60% immune cell reductions - grafa.com
Tvardi Therapeutics Announces Phase 1 Results For TTI-109 And Plans Advancement Into Dermatologic And Gastrointestinal Diseases - marketscreener.com
Tvardi reports phase 1 results for STAT3 inhibitor TTI-109 - Investing.com
Tvardi Therapeutics Reports Phase 1 Data for TTI-109 - TipRanks
Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement - The Manila Times
Tvardi Therapeutics reports Phase 1 TTI-109 data showing bioequivalence to TTI-101, improved tolerability - TradingView
Tvardi Therapeutics (NASDAQ: TVRD) unveils Phase 1 TTI-109 data and plans Phase 2 trials - Stock Titan
Tvardi says TTI-109 matched exposure, cut diarrhea in phase 1 - Stock Titan
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Tvardi Therapeutics Inc. Actuals & Estimates (NASDAQ:TVRD) - TradingView
Price to book forward of Tvardi Therapeutics, Inc. – NASDAQ:TVRD - TradingView
Enterprise value to EBIT forward of Tvardi Therapeutics, Inc. – NASDAQ:TVRD - TradingView
Enterprise value to revenue forward of Tvardi Therapeutics Inc. – MUN:69C - TradingView
Price to earnings forward of Tvardi Therapeutics Inc. – MUN:69C - TradingView
Tvardi Therapeutics Inc. Actuals & Estimates (LSE:0HTC) - TradingView
Price to earnings forward of Tvardi Therapeutics Inc. – LSE:0HTC - TradingView
TVRD Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBITDA forward of Tvardi Therapeutics, Inc. – NASDAQ:TVRD - TradingView
H.C. Wainwright Maintains Tvardi Therapeutics(TVRD.US) With Buy Rating, Maintains Target Price $9 - Moomoo
SGMOQ Stock Price and Chart — OTC:SGMOQ - TradingView
Price to sales forward of Tvardi Therapeutics, Inc. – NASDAQ:TVRD - TradingView
Price to sales forward of Tvardi Therapeutics Inc. – LSE:0HTC - TradingView
TVRD PE Ratio & Valuation, Is TVRD Overvalued - Intellectia AI
Tvardi Therapeutics Ord Shs (TVRD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tvardi Therapeutics Ord Shs (TVRD) Institutional Confidence - TradingKey
Tvardi Therapeutics Ord Shs (TVRD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tvardi Therapeutics (TVRD) Slides as Stock Approaches Key Support Near $2.51Growth ETF - newsline.com
TVRD Q1 2026 Earnings: Narrowed Loss Per Share Beats Expectations Amid Pipeline ProgressEstimate Dispersion - newsline.com
Tvardi Therapeutics Shareholders Approve Directors and Governance Measures - The Globe and Mail
Tvardi Therapeutics Inc. (TVRD) Q1 2026 Earnings: Beats EPS Estimates Amid Continued R&D Progress - newsline.com
Tvardi Therapeutics (TVRD) grants 6,000 stock options to director - Stock Titan
Tvardi Therapeutics (TVRD) director granted 6,000 options at $2.78 exercise price - Stock Titan
Tvardi Therapeutics (TVRD) director Sujal Shah awarded 6,000 stock options at $2.78 - Stock Titan
Tvardi Therapeutics (TVRD) director receives grant of 6,000 stock options at $2.78 - Stock Titan
Tvardi Therapeutics (TVRD) director awarded 6,000 stock options at $2.78 - Stock Titan
Tvardi Therapeutics (TVRD) investors approve directors, say-on-pay and Deloitte as 2026 auditor - Stock Titan
Tvardi Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Shiff Susan Ph.D. - Moomoo
Tvardi Therapeutics (TVRD) Declines 2.88% as Stock Tests Key Support; Near-Term Outlook Hinges on $2.56 FloorFactor Momentum - newsline.com
Tvardi Therapeutics (TVRD) Dips 2.88% as Shares Test Near-Term SupportLeading Diagonal - dars.gov.et
This Cerebras Systems analyst begins coverage on a bullish note; here are top 3 initiations for Monday - MSN
Tvardi Therapeutics Inc Stock (TVRD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.17%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):